CardioGenics (CGNH) 10-K 26 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2015	Feb. 12, 2016
Document And Entity Information
Entity Registrant Name	CardioGenics Holdings Inc.
Entity Central Index Key	1,089,029
Document Type	10-K
Document Period End Date	Oct. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity's Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 2,655,111
Entity Common Stock Shares Outstanding		92,866,724
Trading Symbol	CGNH
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Current Assets
Cash and Cash Equivalents	$ 49,875	$ 70,676
Accounts Receivable		228
Refundable Taxes Receivable	$ 2,385	2,625
Total Current Assets	52,260	73,529
Long-Term Assets
Property and equipment, net	35,174	42,693
Deposits and prepaid expenses	41,558	45,576
Patents, net	102,940	108,132
Totals	231,932	269,930
Current Liabilities
Accounts payable and accrued expenses	1,244,446	1,020,809
Funds held in trust for redemption of class B Common Shares	4	4
Due to shareholders	133,773	131,052
Notes payable, net of debt discount	72,614	71,863
Derivative liability on notes payable	344,086	201,260
Total Liabilities	$ 1,794,923	$ 1,424,988
Commitments and contingencies
Shareholders' Deficiency
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 92,214,030 and 47,383,379 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as at October 31, 2015 and 2014, respectively	$ 1,139	$ 692
Additional paid-in capital	47,838,139	46,505,954
Accumulated deficit	(49,554,070)	(47,637,746)
Accumulated other comprehensive income (expense)	151,801	(23,958)
Total Shareholders' deficiency	(1,562,991)	(1,115,058)
Totals	$ 231,932	$ 269,930

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2015	Oct. 31, 2014
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	92,214,030	47,383,379
Common stock, shares outstanding	92,214,030	47,383,379
Exchangeable Shares [Member]
Common stock, shares issued	24,176,927	24,176,927
Common stock, shares outstanding	24,176,927	24,176,927

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Income Statement [Abstract]
Revenue
Operating Expenses
Depreciation and Amortization of Property and Equipment	$ 7,519	$ 10,803
Amortization of Patent Application Costs	7,248	10,300
General and Administrative	541,585	451,468
Research and Product Development, Net of Investment Tax Credits	215,790	500,935
Total operating expenses	772,142	973,506
Operating Loss	(772,142)	(973,506)
Other Expenses
Interest Expense and Bank Charges (Net)	475,745	1,841,373
Loss (Gain) on Change in Value of Derivative Liability	611,427	(142,054)
Loss on Foreign Exchange Transactions	57,010	7,051
Total other expenses	1,144,182	1,706,370
Net Loss	$ (1,916,324)	$ (2,679,876)
Basic and Fully Diluted Net Loss per Common Share	$ (0.02)	$ (0.04)
Weighted-average number of Common Shares	94,424,039	61,701,832

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Statement of Comprehensive Income [Abstract]
Net Loss	$ (1,916,324)	$ (2,679,876)
Other comprehensive income, currency translation adjustments	175,759	93,557
Comprehensive loss	$ (1,740,565)	$ (2,586,319)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficiency - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Common Stock [Member]
Balance	$ 692	$ 565
Balance, shares	71,560,306	58,903,595
Issuance of common shares on conversion of notes payable January 2014		$ 1
Issuance of common shares on conversion of notes payable January 2014, shares		100,000
Issuance of common shares on settlement of suit January 2014		$ 7
Issuance of common shares on settlement of suit January 2014, shares		700,000
Issuance of common shares for cash January 2014		$ 2
Issuance of common shares for cash January 2014, shares		200,000
Issuance of common shares on conversion of shares of subsidiary		$ 3
Issuance of common shares on conversion of shares of subsidiary, shares		296,538
Issuance of common shares on conversion of notes payable February 2014		$ 2
Issuance of common shares on conversion of notes payable February 2014, shares		154,658
Issuance of common shares on conversion of notes payable March 2014		$ 1
Issuance of common shares on conversion of notes payable March 2014, shares		150,000
Issuance of common shares on conversion of notes payable April 2014		$ 2
Issuance of common shares on conversion of notes payable April 2014, shares		160,000
Issuance of common shares for services rendered March 2014		$ 1
Issuance of common shares for services rendered March 2014, shares		83,333
Issuance of common shares for services rendered April 2014		$ 0
Issuance of common shares for services rendered April 2014, shares		32,946
Issuance of common shares on conversion of notes payable May 2014		$ 3
Issuance of common shares on conversion of notes payable May 2014, shares		258,333
Issuance of common shares for services rendered July 2015		$ 1
Issuance of common shares for services rendered July 2015, shares		63,336
Issuance of common shares on conversion of notes payable August 2014		$ 2
Issuance of common shares on conversion of notes payable August 2014, shares		250,000
Issuance of common shares on conversion of debentures payable September 2014		$ 94
Issuance of common shares on conversion of debentures payable September 2014, shares		9,427,576
Issuance of common shares for services rendered September 2014		$ 5
Issuance of common shares for services rendered September 2014, shares		500,000
Issuance of common shares on conversion of notes payable October 2014		$ 3
Issuance of common shares on conversion of notes payable October 2014, shares		280,000
Issuance of common shares on conversion of notes payable November 2014	$ 6
Issuance of common shares on conversion of notes payable November 2014, shares	589,679
Issuance of common shares on conversion of notes payable December 2014	$ 30
Issuance of common shares on conversion of notes payable December 2014, shares	2,977,637
Issuance of common shares on conversion of notes payable January 2015	$ 73
Issuance of common shares on conversion of notes payable January 2015, shares	7,349,902
Issuance of common shares on conversion of shareholder's loan February 2015	$ 2
Issuance of common shares on conversion of shareholder's loan February 2015, shares	227,273
Issuance of common shares on conversion of notes payable February 2015	$ 72
Issuance of common shares on conversion of notes payable February 2015, shares	7,220,309
Issuance of common shares on conversion of notes payable March 2015	$ 30
Issuance of common shares on conversion of notes payable March 2015, shares	3,039,913
Issuance of common shares on conversion of notes payable April 2015	$ 7
Issuance of common shares on conversion of notes payable April 2015, shares	718,390
Issuance of common shares on conversion of notes payable May 2015	$ 59
Issuance of common shares on conversion of notes payable May 2015, shares	5,894,104
Issuance of common shares for cash May 2015	$ 16	$ 50,000
Issuance of common shares for cash May 2015, shares	1,600,000	200,000
Issuance of common shares on conversion of notes payable June 2015	$ 13
Issuance of common shares on conversion of notes payable June 2015, shares	1,345,834
Issuance of common shares on conversion of notes payable August 2015	$ 56
Issuance of common shares on conversion of notes payable August 2015, shares	5,566,831
Issuance of common shares for services rendered August 2015	$ 1
Issuance of common shares for services rendered August 2015, shares	100,000
Issuance of common shares on conversion of notes payable September 2015	$ 48
Issuance of common shares on conversion of notes payable September 2015, shares	4,763,590
Issuance of common shares on conversion of notes payable October 2015	$ 34
Issuance of common shares on conversion of notes payable October 2015, shares	3,437,189
Settlement of derivative value of notes payable on conversion to common shares
Net Loss
Currency Translation Adjustment
Balance	$ 1,139	$ 692
Balance, shares	116,390,957	71,560,306
Additional Paid-In Capital [Member]
Balance	$ 46,505,954	$ 44,514,000
Issuance of common shares on conversion of notes payable January 2014		12,066
Issuance of common shares on settlement of suit January 2014		188,993
Issuance of common shares for cash January 2014		49,998
Issuance of common shares on conversion of shares of subsidiary		(356,227)
Issuance of common shares on conversion of notes payable February 2014		18,557
Issuance of common shares on conversion of notes payable March 2014		14,894
Issuance of common shares on conversion of notes payable April 2014		12,478
Issuance of common shares for services rendered March 2014		17,916
Issuance of common shares for services rendered April 2014		7,083
Issuance of common shares on conversion of notes payable May 2014		15,497
Issuance of common shares for services rendered July 2015		8,233
Issuance of common shares on conversion of notes payable August 2014		14,998
Issuance of common shares on conversion of debentures payable September 2014		1,035,239
Beneficial conversion charge from re-pricing of shares and warrants associated with converted debentures		745,121
Issuance of common shares for services rendered September 2014		67,495
Issuance of common shares on conversion of notes payable October 2014		13,487
Issuance of common shares on conversion of notes payable November 2014	22,528
Issuance of common shares on conversion of notes payable December 2014	32,230
Issuance of common shares on conversion of notes payable January 2015	83,051
Issuance of common shares on conversion of shareholder's loan February 2015	22,854
Issuance of common shares on conversion of notes payable February 2015	57,391
Issuance of common shares on conversion of notes payable March 2015	23,524
Issuance of common shares on conversion of notes payable April 2015	10,720
Issuance of common shares on conversion of notes payable May 2015	51,301
Issuance of common shares for cash May 2015	39,984
Issuance of common shares on conversion of notes payable June 2015	18,472
Issuance of common shares on conversion of notes payable August 2015	45,216
Issuance of common shares for services rendered August 2015	3,044
Issuance of common shares on conversion of notes payable September 2015	34,778
Issuance of common shares on conversion of notes payable October 2015	43,234
Settlement of derivative value of notes payable on conversion to common shares	$ 843,858	126,126
Net Loss
Currency Translation Adjustment
Balance	$ 47,838,139	46,505,954
Accumulated Deficit [Member]
Balance	$ (47,637,746)	(44,957,870)
Issuance of common shares on conversion of notes payable November 2014
Issuance of common shares on conversion of notes payable December 2014
Issuance of common shares on conversion of notes payable January 2015
Issuance of common shares on conversion of shareholder's loan February 2015
Issuance of common shares on conversion of notes payable February 2015
Issuance of common shares on conversion of notes payable March 2015
Issuance of common shares on conversion of notes payable April 2015
Issuance of common shares on conversion of notes payable May 2015
Settlement of derivative value of notes payable on conversion to common shares
Net Loss	$ (1,916,324)	(2,679,876)
Currency Translation Adjustment
Balance	$ (49,554,070)	(47,637,746)
Accumulated Other Comprehensive Income (Loss) [Member]
Balance	$ (23,958)	(117,515)
Issuance of common shares on conversion of notes payable November 2014
Issuance of common shares on conversion of notes payable December 2014
Issuance of common shares on conversion of notes payable January 2015
Issuance of common shares on conversion of shareholder's loan February 2015
Issuance of common shares on conversion of notes payable February 2015
Issuance of common shares on conversion of notes payable March 2015
Issuance of common shares on conversion of notes payable April 2015
Issuance of common shares on conversion of notes payable May 2015
Settlement of derivative value of notes payable on conversion to common shares
Net Loss
Currency Translation Adjustment	$ 175,759	93,557
Balance	$ 151,801	(23,958)
Noncontrolling Interest [Member]
Balance		(356,224)
Issuance of common shares on conversion of shares of subsidiary		$ 356,224
Balance
Balance	$ (1,115,058)	$ (917,044)
Issuance of common shares on conversion of notes payable January 2014		12,067
Issuance of common shares on settlement of suit January 2014		189,000
Issuance of common shares for cash January 2014		$ 50,000
Issuance of common shares on conversion of shares of subsidiary
Issuance of common shares on conversion of notes payable February 2014		$ 18,559
Issuance of common shares on conversion of notes payable March 2014		14,895
Issuance of common shares on conversion of notes payable April 2014		12,480
Issuance of common shares for services rendered March 2014		17,917
Issuance of common shares for services rendered April 2014		7,083
Issuance of common shares on conversion of notes payable May 2014		15,500
Issuance of common shares for services rendered July 2015		8,234
Issuance of common shares on conversion of notes payable August 2014		15,000
Issuance of common shares on conversion of debentures payable September 2014		1,035,333
Beneficial conversion charge from re-pricing of shares and warrants associated with converted debentures		745,121
Issuance of common shares for services rendered September 2014		67,500
Issuance of common shares on conversion of notes payable October 2014		13,490
Issuance of common shares on conversion of notes payable November 2014	22,534
Issuance of common shares on conversion of notes payable December 2014	32,260
Issuance of common shares on conversion of notes payable January 2015	83,124
Issuance of common shares on conversion of shareholder's loan February 2015	22,856
Issuance of common shares on conversion of notes payable February 2015	57,463
Issuance of common shares on conversion of notes payable March 2015	23,554
Issuance of common shares on conversion of notes payable April 2015	10,727
Issuance of common shares on conversion of notes payable May 2015	51,360
Issuance of common shares for cash May 2015	$ 40,000
Issuance of common shares for cash May 2015, shares	1,600,000
Issuance of common shares on conversion of notes payable June 2015	$ 18,485
Issuance of common shares on conversion of notes payable August 2015	45,272
Issuance of common shares for services rendered August 2015	3,045
Issuance of common shares on conversion of notes payable September 2015	34,826
Issuance of common shares on conversion of notes payable October 2015	43,268
Settlement of derivative value of notes payable on conversion to common shares	843,858	126,126
Net Loss	(1,916,324)	(2,679,876)
Currency Translation Adjustment	175,759	93,557
Balance	$ (1,562,991)	$ (1,115,058)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Cash flows from operating activities:
Net loss	$ (1,916,324)	$ (2,679,876)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Depreciation and amortization	7,519	10,803
Amortization of Patent Application Costs	7,248	10,300
Loss (Gain) on Change in Value of Derivative Liability	611,427	(142,054)
Interest and Discount on Notes Payable	$ 452,323	494,242
Amortization of Discount on Debentures Payable		615,252
Common Stock Issued for Services Rendered	$ 3,045	100,734
Beneficial conversion charge included in interest expense		745,121
Changes in working capital items:
Account Receivable	$ 228	18
Deposits and Prepaid Expenses	4,018	3,691
Refundable Taxes Receivable	$ 240	677
Government Grants and Investment Tax Credits, Receivable		60,104
Accounts Payable and Accrued Expenses	$ 223,637	183,877
Net cash used in operating activities	(606,639)	$ (597,111)
Cash flows from investing activities:
Patent Application Costs	(2,057)
Net cash used in investing activities	(2,057)
Cash flows from financing activities:
Due to Shareholders	23,914	$ 131,052
Payment on Notes Payable	(4,291)
Proceeds From Notes Payable	305,000	$ 215,000
Issue of Common Shares for Cash	40,000	50,000
Net cash provided by financing activities	364,623	396,052
Effects of exchange rate changes on cash and cash equivalents	223,272	8,632
Net Decrease in cash and cash equivalents	(20,801)	(192,427)
Cash and cash equivalents, beginning of year	70,676	263,103
Cash and cash equivalents, end of year	$ 49,875	$ 70,676

Nature of Business

Nature of Business	12 Months Ended
	Oct. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business The accompanying audited consolidated financial statements have been prepared in accordance with the requirements of Form 10-K and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and include the results of CardioGenics, Inc. and its subsidiaries and JAG Media Holdings, Inc and its subsidiaries (“JAG Media”) (from July 31, 2009, date of acquisition) which are collectively referred to as the “Company.” CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products for the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development. In the last quarter of 2011 CardioGenics commenced selling one of these products, but has generated no significant revenue therefrom.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Oct. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at October 31, 2015 of approximately $49.6 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing. While the Company believes it will be successful in obtaining the necessary financing to fund its operations, and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies (a) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All significant intercompany transactions and balances have been eliminated. (b) Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. (c) Government Grants and Investment Tax Credits Receivable The Company’s accounts include claims for investment tax credits (“ITCs”) relating to scientific research activities of the Company prior to July 31, 2009. The qualification and recording of this activity for ITCs purposes is established by Canadian Income Tax authorities when the income tax returns for the period are assessed. ITCs were recognized in the statement of operations in the year in which the expenses were incurred. The Company no longer qualifies to receive substantial refunds of ITCs resulting from scientific research. Currently the majority of ITCs resulting from scientific research are carried forward to a time when the Company becomes tax paying at which time said ITCs are applicable against taxes payable. (d) Property and Equipment Property and equipment is recorded at cost. Property and equipment is depreciated using methods and rates as follows: Furniture and Fixtures 20% declining balance Lab Equipment 20% declining balance Computer Equipment – Hardware 30% declining balance Computer Equipment – Software 50% declining balance Leasehold Improvements Straight-line over the lesser of the life of the asset or the life of the lease (e) Patents Capitalized patent costs represent legal and application costs incurred to establish patents. Capitalized patent costs are amortized on a straight-line method over the related patent term. As patents are abandoned, the net book value of the patent is written off. (f) Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of long-lived assets under the guidance of standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. (g) Research and Development Costs Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of prototype products, including payroll costs. Amounts expected to be received from governments under Scientific Research Tax Credit arrangements are offset against current expenses. The Company recognizes revenue from restricted grants in the period in which the Company has incurred the expenditures in compliance with the specific restrictions. (h) Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in the authoritative guidance. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As there is no certainty that the Company will generate taxable income in the foreseeable future to utilize tax losses accumulated to date, no provision for ultimate tax reduction has been made in these financial statements. On November 1, 2007, the Company adopted the guidance issued for accounting for uncertainty in income taxes which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of the guidance and in subsequent periods. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as general and administrative expense. There are no uncertain tax positions as of October 31, 2015 and 2014. (i) Stock-Based Compensation The Company follows the authoritative guidance for stock-based compensation which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company has also considered the related guidance of the SEC. The Company estimates the fair value of stock options and shares issued as compensation to employees and directors as of the date of grant using the Black-Scholes pricing model and restricted stock based on the per share value. The Company also follows the guidance for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants which provides guidance on transactions in which (1) the fair value of the equity instruments is more reliably measurable than the fair value of the goods or services received and (2) the counterparty receives shares of stock, stock options, or other equity instruments in settlement of the entire transaction or, if the transaction is part cash and part equity instruments, in settlement of the portion of the transaction for which the equity instruments constitute the consideration. Options issued with a nominal exercise price in exchange for services rendered were measured at the fair value of the underlying services rendered on the date of grant. The expense is recorded to the statement of operations with a corresponding increase in share capital with no additional increase in the number of shares as they were legally not yet exercised. (j) Net Loss Per Common Share Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on loss per share. (k) Comprehensive Income (Loss) Other comprehensive income (loss) includes the foreign currency translation adjustments. (l) Concentration of Credit Risk The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions. (m) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. By their nature, these estimates are subject to uncertainty and the effect on the consolidated financial statements of changes in such estimates in future periods could be material. (n) Foreign Currency Translation The Company maintains its accounting records for its Canadian operations in Canadian dollars. Transactions in United States dollars (“USD”) are translated into Canadian dollars at rates in effect at the date of the transaction and gains or losses on such transactions are recorded at the time of settlement in the statement of operations. The Company’s reporting currency is the USD. Foreign denominated assets and liabilities of the Company are translated into USD at the prevailing exchange rates in effect at the end of the reporting period, the historical rate for stockholders’ deficiency and a weighted average of exchange rate in effect during the period for expenses, gains and losses. Adjustments that arise from translation into the reporting currency are recorded in the accumulated other comprehensive income (loss) component of stockholders’ deficiency. (o) Financial Instruments The carrying values of cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature. Notes payable and convertible debentures approximate their fair value based upon recent issuances of the underlying debt. (p) Derivative Instruments The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date. (q) Beneficial Conversion Charge The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values. (r) Recently Issued Accounting Standards Revenue From Contracts With Customers In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods and services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 as amended is effective for the Company beginning in fiscal 2019. The Company is currently evaluating the impact of this pronouncement on its consolidated financial statements. Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Property and Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	4. Property and Equipment The costs and accumulated depreciation and amortization of property and equipment are summarized as follows: October 31, 2015 2014 Furniture and Fixtures $ 12,120 $ 12,120 Lab Equipment 168,481 168,481 Computer Hardware 19,490 19,490 Computer Software 8,433 8,433 Leasehold Improvements 91,269 91,269 Total Property and Equipment 299,793 299,793 Less Accumulated Depreciation and Amortization 264,619 257,100 Property and Equipment, Net $ 35,174 $ 42,693 Depreciation and amortization expense amounted to $7,519 and $10,803 for the years ended October 31, 2015 and 2014, respectively.

Patents

Patents	12 Months Ended
	Oct. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	5. Patents The costs and accumulated amortization of patents are summarized as follows: October 31, 2015 2014 Patents $ 146,079 $ 144,022 Less: Accumulated Amortization (43,139 ) (35,890 ) Patents, Net $ 102,940 $ 108,132 Weighted-Average Life 17 Years 17 Years Amortization expense amounted to $7,248 and $10,300 for the years ended October 31, 2015 and 2014, respectively. Amortization expense is expected to be approximately $7,250 per year for the years ended October 31, 2016 through 2020.

Due to Shareholders

Due to Shareholders	12 Months Ended
	Oct. 31, 2015
Notes to Financial Statements
Due to Shareholders	6. Due to Shareholders The amount due to shareholders is due on demand and carries interest at 10% per annum.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the consolidated financial statements. The Company has incurred losses in Canada since inception which have generated net operating loss carryforwards “NOLs” for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of October 31, 2015 were $7,457,000 which will expire from 2016 through 2035. All fiscal years except 2015 have been assessed. Research and development tax credit for 2012 for which the Company received a refund of $81,460 is being refuted by Canadian taxation authorities. The Company is disputing the position taken by the taxation authorities but has established a reserve against possible repayment. As of October 31, 2015, the Company had NOLs from US sources of approximately $45,532,000 available to reduce future Federal taxable income which will expire from 2020 through 2034. Returns for the years 2008 through 2015 are yet to be filed. As of October 31, 2015, the Company has recorded approximately $408,000 of estimated penalties and interest related to this matter. Internal Revenue Code Section 382 (“Section 382”) imposes a limitation on a corporation’s ability to utilize NOLs if it experiences an ownership change. In general, an ownership change may occur from certain transactions that increase the ownership of 5% stockholders in the stock of a corporation by more than 50 percentage points over a three year period. If an ownership change occurs, utilization of the NOLs would be subject to an annual limitation. The annual limitation under Section 382 is calculated by multiplying the value of the stock at the time of the ownership change by the applicable long-term exempt rate. Any unused annual limitation may be carried over to later years. The Company has historically been in a loss position and, therefore, the Section 382 limitation may not be relevant for the current period. For the years ended October 31, 2015 and 2014, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded. As of October 31, 2015 and 2014, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: October 31, 2015 2014 Temporary: Property and equipment $ 21,990 $ (24,092 ) Net operating loss carryforwards 17,568,933 18,640,188 Unrealized foreign exchange (71,958 ) 23,175 Investment tax credits 402,189 402,189 Transitional tax debits (25,076 ) (25,076 ) Unrealized loss (gain) on derivative liability 157,104 (37,181 ) Total Deferred Tax Assets 18,009,202 18,979,203 Valuation Allowance (18,009,202 ) (18,979,203 ) Net Deferred Income Taxes $ ▬ $ ▬ A reconciliation of the Canadian combined statutory rate to the Company’s effective tax rate for the years ended October 31, 2015 and 2014 is as follows: October 31, 2015 2014 Statutory rate 28 % 28 % Decrease in income tax rate resulting from: Permanent differences (6.0 )% (1.3 )% Change in valuation allowance (22.0 )% (26.7 )% Effective tax rate 0.0 % 0.0 %

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Oct. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	8. Accounts Payable and Accrued Expenses October 31, 2015 2014 Accounts Payable $ 181,102 $ 289,054 Income Tax Reserve 487,460 321,460 Research and Development 188,458 17,004 Investor Relations 10,104 11,738 Patent Application Costs 2.419 5,026 Legal Fees 301,154 316,127 Stock Exchange Listing 15,384 ▬ Accounting Fees 58,355 60,400 Total $ 1,244,446 $ 1,020,809

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Oct. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation The Company follows the guidance for stock-based compensation. Stock-based employee compensation related to stock options for each of the years ended October 31, 2015 and 2014 amounted to $0. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Weighted Average Exercise Options Price Outstanding – October 31, 2013 30,000 $ 0.90 Granted ▬ ▬ Forfeited/expired ▬ ▬ Exercised ▬ ▬ Outstanding – October 31, 2014 30,000 $ 0.90 Granted ▬ ▬ Forfeited/expired ▬ ▬ Exercised ▬ ▬ Outstanding – October 31, 2015 30,000 $ 0.90 Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at October 31, 2015 and 2014. The fair value of each option granted is estimated on grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The Company granted no stock options during the years ended October 31, 2015 and 2014. The following table summarizes information on stock options outstanding at October 31, 2015 Options Outstanding and Exercisable Weighted Number Weighted Average Outstanding Average Remaining Aggregate at Exercise Life Intrinsic October 31, 2015 Price (Years) Value 30,000 $ 0.90 3.75 30,000 3.75 $ 0 The intrinsic value is calculated as the difference between the market value as of October 31, 2015 and the exercise price of the shares. The market value as of October 31, 2015 was $0.04 as reported by the OTC Bulletin Board.

Notes Payable

Notes Payable	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	10. Notes Payable On November 19, 2012, the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months, the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owning more than 4.99% of the common stock outstanding. In June 22, 2015, the Company and the lender entered into a settlement agreement, whereby in exchange for a remaining indebtedness of $77,235, the Company agreed that on the 15th of each month commencing July 2015 and ending June 2016, the Company would either pay the lender $6,436 or issue to the lender common shares in the equivalent dollar amount at a price equal to the average closing price of the common stock in the five trading days prior to the scheduled payment date. During 2015, the Company paid one installment in cash and a total of 655,150 common shares for three installments. On May 23, 2014, the Company issued promissory notes (the “LG Notes”) to LG Capital Funding, LLC and Adar Bays, LLC (collectively the “Holders”) in the amount of $52,500 each bearing interest at 8% annually due May 23, 2015. The LG Notes and accrued interest may be converted into shares of the Common Stock of the Company at a 42% discount to the lowest closing bid with a 12 day look back. The LG Notes may be prepaid with the following penalties: (i) if the Notes are prepaid within 60 days of the issue date, then at 130% of the face amount plus any accrued interest; and, (ii) if the LG Notes are prepaid after 60 days after the issue date but less than 181 days after the issue date, then at 140% of the face amount plus any accrued interest. The LG Notes may not be prepaid after the 180 th On November 12, 2014, the Company received $50,000 from Chicago Ventures in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. The notes were all converted to common shares in 2015. On November 20, 2014, the Company reached a settlement with IBC Funds, LLC (“IBC”) whereby IBC agreed to pay $78,026 of the Company’s debts in exchange for the right to purchase shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. The notes were all converted to common shares in 2015. On December 15, 2014, the Company received $52,500 from LG Capital Funding LLC in exchange for a note payable bearing interest at 8% due in one year, convertible into shares in the Company’s common stock at a 42% discount from the lowest closing price of the common shares over the prior 15 days. Notes in the amount of $36,000 were converted to common shares in 2015. On March 25, 2015, the Company received $52,500 from Adar Bays, LLC in exchange for a note payable bearing interest at 8% due November 26, 2015, convertible into shares in the Company’s common stock at a 40% discount from the average of the lowest two trading prices of the common shares over the prior 10 trading days. The notes were all converted to common shares in 2015. On July 31, 2015, the Company received $55,250 from Auctus Private Equity Fund, LLC in exchange for a note payable bearing interest at 8% due in nine months, convertible into shares in the Company’s common stock at a 45% discount from the lowest closing price of the common shares over the prior 15 days. On August 14, 2015, the Company received $27,500 from Iliad Research and Trading LLC in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. On October 13 2015, the Company received $27,500 from Iliad Research and Trading LLC in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days. A summary of the Notes at October 31, 2015 and 2014 is as follows: October 31, 2015 October 31, 2014 Convertible Note Payable, due February 20, 2015 $ - $ 12,529 Convertible Notes Payable, due May 23, 2015 - 105,000 Convertible Note Payable, due June 23, 2016 54,925 40,000 Convertible Note Payable, due October 22, 2015 - 35,000 Convertible Note Payable, due November 26, 2015 55,250 - Convertible Note Payable, due December 15, 2015 16,500 - Convertible Note Payable, due August 14, 2016 27,500 - Convertible Note Payable, due October 13, 2016 27,500 - Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $72,614 and $71,863 (109,061 ) (120,666 ) Total 72,614 71,863 Less: Current portion 72,614 71,863 Total Long-term portion $ - $ - As described in further detail in Note 11, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. The discount to the Notes is amortized to interest expense over the life of the Note or until conversion. Upon conversion of the Notes and related interest and original issue discount to common stock, any remaining unamortized discount is charged to financing expense. During the year ended October 31, 2015, Notes in the principal amount of $422,874 were exchanged for 42,903,378 common shares.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Oct. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	11. Derivative Liabilities Convertible notes - embedded conversion features: The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value. The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $344,086 (2014- $201,260) as of October 31, 2015. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying consolidated statements of operations. The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price of $.017 and $.018 per share according to the agreements; risk free interest rate of .11%; expected life of 1 year; expected dividend of zero; a volatility factor of 241% to 272%, as of October 31, 2015 and 2014. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Oct. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. FAIR VALUE MEASUREMENTS As defined by the Accounting Standard Codification, fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below: ● Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities. ● Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals. ● Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity. The following table summarizes the financial liabilities measured at fair value on a recurring basis as of October 31, 2015 and 2014, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value: Quoted Prices in Significant Other Significant Total Increase (Reduction) Active Markets for Observable Unobservable in Fair Value Balance Sheet Identical Assets or Inputs Inputs October 31, 2014 Recorded at Location Liabilities (Level 1) (Level 2) (Level 3) Total October 31, 2014 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 201,260 $ 201,260 $ (142,054) Quoted Prices in Significant Other Significant Total Increase (Reduction) Active Markets for Observable Unobservable in Fair Value Balance Sheet Identical Assets or Inputs Inputs October 31, 2015 Recorded at Location Liabilities (Level 1) (Level 2) (Level 3) Total October 31, 2015 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 344,086 $ 344,086 $ 611,427 The Company utilizes the Black-Scholes Option Pricing model to estimate the fair value of the derivative liability associated with the convertible note obligation. The Company considers them to be Level 3 instruments. The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the derivative liability at October 31, 2015 and 2014: 2015 2014 Fair value $0.017-0.018 $0.058-0.060 Expected volatility 241-272 % 162%-169 % Dividend yield - - Expected term (in years) .06 - .95 .31-.94 Risk-free interest rate 0.11 % 0.11 % The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the year ended October 31, 2015. 2015 2014 Balance at beginning of year $ 201,260 $ 99,702 Additions to derivative instruments 375,257 369,738 Change in fair value of derivative liabilities 611,427 (142,054 ) Settlements (843,858 ) (126,126 ) Balance at end of year $ 344,086 $ 201,260

Debentures Payable

Debentures Payable	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
Debentures Payable	13. Debentures Payable In February 2013, loans from shareholder/directors in the amount of $288,584 were converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.25 per share at any time up to three years. In May 2013, the Company sold Series B Convertible Debenture Units (the “B Units”) in the amount of $500,000. Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years. In June 2013, the Company sold Series B Convertible Debenture Units (the “B Units”) in the amount of $148,653 to officers and/or directors. Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years. The Company allocated proceeds of $306,900 to the fair value of the warrants using a Black Scholes model with the following assumptions: conversion price $0.25 or $0.15 per share according to the agreements; risk free interest rate of .18%; expected life of 3 years; expected dividend of zero; a volatility factor of 176% to 195%, as of October 31, 2013 and the remaining $343,996 to the fair value of the Series B Convertible Debentures. Based on the excess of the aggregate fair value of the common shares that would have been issued if the Series B Convertible Debentures had been converted immediately over the proceeds allocated to the Series B Convertible Debentures, the investors received a beneficial conversion feature that had an aggregate intrinsic value of $343,996 as of the commitment date. Accordingly, the Company recorded an increase in additional paid-in capital and debt discount of $650,896 in connection with the issuance of the Series B Convertible Debentures and warrants. On September 17, 2014, the Series A and Series B Convertible Debentures plus acquired interest were converted to 9,427,576 common shares. The conversion price of both Series A and Series B Convertible Debentures was reduced to $0.11 at the conversion date. The reduction in conversion price from $0.25 to $0.11 to induce the conversion resulted in additional beneficial conversion charge of $745,121 during the year ended October 31, 2014.

Warrants

Warrants	12 Months Ended
	Oct. 31, 2015
Equity [Abstract]
Warrants	14. Warrants Outstanding warrants are as follows: October 31, 2015 2014 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including February 27, 2016 600,000 600,000 Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.14 per common share up to and including June 3, 2016 750,000 750,000 Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 232,500 232,500 Issued to consultants August 5, 2013, entitling the holders to purchase 2,500,000 common shares in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023 2,500,000 2,500,000 Issued to consultants August 5, 2013, entitling the holders to purchase 1,500,000 common shares in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023 1,500,000 1,500,000 Issued to consultant September 3, 2013, entitling the holder to purchase 500,000 common shares in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018 500,000 500,000 Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016 250,000 250,000 Issued to shareholder November 7, 2013, entitling the holder to purchase 1 common shares in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 125,000 125,000 Total Warrants outstanding 8,457,500 8,457,500

Authorized Share Capital

Authorized Share Capital	12 Months Ended
	Oct. 31, 2015
Equity [Abstract]
Authorized Share Capital	15. Authorized Share Capital On September 30, 2009, the Company’s articles of incorporation were amended to increase the total number of common shares authorized for issuance from 500,000,000 shares to 650,000,000 shares of common stock, par value $0.00001 per share. On April 23, 2010, the Company’s Board of Directors approved a reverse stock split of its issued and outstanding common shares. The total authorized shares was at the same time reduced to 65,000,000. The Board of Directors selected a ratio of one-for-ten and the reverse split was effective June 20, 2010. As a result, the total number of shares of all classes of capital stock authorized for issuance by the Company decreased from 700,440,000 shares to 70,044,000 shares with a par value of $.00001 per share, of which 5,000,000 shares are authorized for issuance as preferred stock, 65,000,000 shares are authorized for issuance as common stock, 40,000 shares are authorized for issuance as Series 2 Class B common stock and 4,000 shares are authorized for issuance as Series 3 Class B common stock. On January 17, 2013 the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation to increase the authorized common shares to 150,000,000 and de-authorize the Company’s Class B common stock.

Issuance of Common Stock

Issuance of Common Stock	12 Months Ended
	Oct. 31, 2015
Equity [Abstract]
Issuance of Common Stock	16. Issuance of Common Stock During the year ended October 31, 2015 and 2014, the Company issued the following common shares: Year Ended October 31, 2015 Year Ended October 31, 2014 # of shares Amount # of shares Amount Issuance to third parties for services rendered 100,000 $ 3,045 679,615 $ 100,734 Issuance to third parties for cash 1,600,000 $ 40,000 200,000 $ 50,000 Issuance to third parties on exercise of conversion of notes payable 42,903,378 $ 422,874 1,352,991 $ 101,991 Issued to shareholder on conversion of shareholder’s loan 227,273 $ 22,856 - $ - Issued to debenture holders on exercise of conversion of debentures payable - $ - 9,427,576 $ 1,035,333 Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company. - $ - 296,538 $ - The fair value of shares issued for services rendered were measured at the fair value of the services rendered on the date rendered. The Company has reserved in Treasury 24,700,000 Common Shares for possible conversion exercise of options, warrants and debt.

Redemption of Class B Common St

Redemption of Class B Common Stock	12 Months Ended
	Oct. 31, 2015
Redemption Of Class B Common Stock
Redemption of Class B Common Stock	17. Redemption of Class B Common Stock On or about February 28, 2011 CardioGenics Holdings Inc. (“Holdings”) mailed notices to the holders of its outstanding Series 2 Class B Common Stock (the “Series 2 Shares”) and Series 3 Class B Common Stock (the “Series 3 Shares”), which notify such stockholders that Holdings has elected to redeem all outstanding Series 2 Shares and Series 3 Shares in accordance with their terms. The Redemption Date was April 4, 2011 and the Redemption Price was par value, $0.00001 per share. Holdings has established a trust account with TD Bank Canada, which account will hold proceeds sufficient to redeem the issued and outstanding Series 2 Shares and Series 3 Shares. Accordingly, notwithstanding that any certificate for Series 2 Shares or Series 3 Shares called for redemption shall not have been surrendered for cancellation, all Series 2 Shares and Series 3 Shares called for redemption shall no longer be deemed outstanding, and all rights with respect to such Series 2 Shares and Series 3 Shares shall forthwith on the Redemption Date cease and terminate, except only the right of the holders thereof to receive the pro-rata amount payable of the Series 2 Shares and Series 3 Shares, without interest.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Oct. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	18. Net Loss per Share The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted (loss) per share: Years Ended October 31, 2015 2014 Weighted-average shares - basic 94,424,039 61,701,832 Effect of dilutive securities ▬ ▬ Weighted-average shares - diluted 94,424,039 61,701,832 Basic (loss) per share (“EPS”) and diluted EPS for the years ended October 31, 2015 and 2014 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants and conversion of debt representing 18,621,774 and 12,195,822 incremental shares, respectively, have been excluded from the years ended October 31, 2015 and 2014, respectively, computation of diluted EPS as they are antidilutive given the net losses generated.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Oct. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	19. Commitments and Contingent Liabilities Lease The Company has entered into an operating lease agreement for the use of operating space. Aggregate minimum annual lease commitments of the Company under the non-cancelable operating lease as of October 31, 2015 are as follows. (The Company is required in addition to pay a proportionate share of building operational expenses.) : Year Amount 2016 $ 42,473 2017 35,394 Total Minimum Lease Payments $ 77,867 Lease expense amounted to $61,137 and $70,374 for the years ended October 31, 2015 and 2014, respectively. The preceding data reflects existing leases and does not include replacements upon their expiration. In the normal course of business, operating leases are generally renewed or replaced by other leases. Lawsuit On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of $514,000. On January 3, 2014, the suit was settled for cash consideration of $10,000 plus 700,000 common shares. The Company is not involved in other litigation as this time.

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Oct. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	20. Supplemental Disclosure of Cash Flow Information For the Year Ended October 31, 2015 2014 Cash paid during the period for: Interest $ 22,551 $ 16,901 Income Taxes ▬ ▬ Non-cash financing activities: Conversion of notes payable including principal, interest and original issue discount 422,874 101,991 Services rendered settled with common shares 3,045 100,734 Value of beneficial conversion feature and warrants issued with debentures issued during the year ▬ 745,121 Settlement of accrued legal by issuance of common shares ▬ 189,000 Settlement of shareholder loan with common shares 22,856 ▬

Subsequent Events

Subsequent Events	12 Months Ended
	Oct. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events 1. On November 4, 2015, the Company, through 2489528 Ontario Inc., an Ontario corporation and indirect subsidiary of the Company (” Acquisition Sub “), Plasticap Corporation, an Ontario corporation (” Plasticap “) and 1731861 Ontario Inc., an Ontario corporation (” 173 Corp “) entered into an asset purchase agreement, dated as of November 2, 2015, pursuant to which Acquisition Sub was to acquire all of the assets of Plasticap and 173 Corp (collectively, the “ Sellers “) (the ” Asset Purchase Agreement “). In consideration for the sale of the assets by the Sellers, the Company is to issue to Sellers, or their nominees (i) a convertible debt instrument, in the original principal amount of ten million Canadian dollars (CDN$10,000,000), which shall bear interest at a rate of 8% (the ” Convertible Debt “); (ii) twenty million (20,000,000) shares of the Company’s common stock, par value $0.00001 ( the ” Common Stock “), which shares shall not be registered for resale by the Company and shall be subject to the rights and restrictions of Rule 144 of the Securities Act of 1933 (” Rule 144 “); and (iii) a warrant to purchase ten million (10,000,000) shares of Common Stock, which warrant shall have a term of three (3) years, be exercisable on a net cashless basis at an exercise price of $0.50 per share, not be registered for resale by Buyer and be subject to the rights and restrictions of Rule 144 (the ” Warrant “). In addition, Acquisition Sub will assume two million nine-hundred thousand Canadian dollars (CDN $2,900,000) in secured debt from Sellers (the ” Secured Debt “) as part of the consideration. The Asset Purchase Agreement contains customary representations and warranties from the parties. Acquisition Sub and 173 Corp also agreed to various post-closing undertakings. On November 4, 2015 and subject to post-closing undertakings, the Company, Acquisition Sub and the Sellers closed the sale and purchase of all of the assets of Sellers by Acquisition Sub, pursuant to the terms of the Asset Purchase Agreement. The assets acquired by Acquisition Sub comprised all of the assets of Sellers, which include, among others, the “Plasticap” trademark, all furnishings, fixtures and equipment related to Plasticap’s specialty cap and closure manufacturing business and all of the Sellers’ customer contracts, all as more particularly set forth in the Asset Purchase Agreement. As part of the closing, Acquisition Sub and 173 Corp agreed to various post-closing undertakings. The following under takings have yet to be completed and hence the sale has not closed and the notes and warrants above have not been issued, nor has the CDN $2,900,000 secured debt been assumed. (i) 173 Corp undertakes that by January 31, 2016 it shall pay all the outstanding indebtedness of Bibby Financial Services located at 4 Robert Speck Parkway, Unit 310, Mississauga, ON, L4Z 1S1. (ii) Following the fulfilment of the undertaking specified in paragraph (i), which shall be considered fulfilled upon 173 Corp providing Acquisition Sub with a copy of the cheque payable to Bibby Financial Services for the full amount of the indebtedness, 173 Corp undertakes to provide Acquisition Sub, or as it directs, with a full and comprehensive release against any future claims Bibby Financial Services may have and a full indemnity against any future claims. (iii) Acquisition Sub undertakes that it will advance up to fifty thousand Canadian dollars (CDN$50,000) as a deposit against any outstanding claims Jacob Van Halteran may have through any security interests duly registered on any of the Sellers’ assets and that Sellers shall provide a full and comprehensive release of those security interests other than any rights that may be asserted under Schedule 2.3 of the Asset Purchase Agreement specifying any assumed liabilities. (iv) A Seller’s lender will be paid fifty thousand Canadian dollars (CDN$50,000) against the debt in 173 Corp. (v) Acquisition Sub undertakes to pay from earnings received from time-to-time from its primary customer contract, based on a calculation of 50% before interest, taxes, depreciation and amortization, amounts to reduce the principle amount of the Secured Debt to zero by December 31, 2018. In the event, a residual balance exists, a balloon payment will be made to complete the payment. After Acquisition Sub completes the payment obligation specified under this subparagraph 6, the Sellers undertake, acknowledge and agree that the Acquisition Sub shall have no further responsibility to make any further payments on the balance of the Secured Debt. (vi) Acquisition Sub and 1646813 Ontario Limited undertake to enter into a new lease agreement for the premises located at 177 Crosby Avenue, Richmond Hill, Ontario, effective November 2015, with an option for Acquisition Sub to purchase the premises on the following terms: The term of the lease will be 5 years, with an option for an additional 5 years. Acquisition Sub has the option to acquire the building until January 15, 2016, through a purchase of all of the outstanding shares of 1646813 Ontario Limited, the owner of the real property and subject to refinancing the existing mortgages. In the event Acquisition Sub does not exercise the option, the lease shall remain in force for the duration of the lease and the Convertible Debt will be reduced by one million (CDN$1,000,000.00) Canadian dollars. The option for acquiring the real property has expired and therefore not in consideration any more. Further, the legal position of both parties is being disputed and has currently not concluded. There are no guarantees that this acquisition will be consummated and if it does, the terms might be different than stated above. The Company has advanced/loaned $288,126 to Acquisition Sub, Plasticap or 173 Corp. from November 4, 2015 to February 12, 2016. The Company is confident of collection of these advances/loans should the acquisition not be consummated. 2. On November 4, 2015, the Company received a loan in the amount of $227,894 from an individual. The loan bears interest at 10% per annum and has no set term. 3. On November 13, 2015, the Company settled $6,436 in JMJ Financial notes payable plus interest with 160,425 common shares. 4. On November 15, 2015, the Company issued a convertible promissory note to “Bay Private Equity Inc. (“Bay”), whereby the Company agrees to pay Bay on November 20, 2016 the sum of $50,000 (“Principal Sum”) plus interest at 8% per annum. Bay has the option to at any time convert the Note into shares of the company’s common stock at a price for each share equal to 55% of the lowest price for any trade of the common stock during the fifteen (15) trading day period prior to conversion. 5. On November 25, 2015, the Company issued a Senior Convertible Promissory Note to Firstfire Global Opportunities Fund LLP (“Firstfire”) whereby the company agrees to pay Firstfire on May 25, 2016 the sum of $160,500 (“Principal Sum”) plus interest at 4% per annum. Should the company fail to pay said Principal Sum plus interest on or before May 25, 2016, Firstfire may convert the Promissory Note into $240,750 worth of common shares at the lower of $.15 per common share or 40% of the lowest selling price of the common shares in the ten (10) days preceding the conversion date. 6. On December 15, 2015, the Company settled $6,436 in JMJ Financial notes payable plus interest with 135,614 common shares. 7. On December 21, 2015, the Company issued to a third party 205,000 common shares for total consideration of $7,279. 8. On December 21, 2015, the Company repaid $7,279 of the loan from an officer/director. 9. On January 15, 2016, the Company settled $6,436 in JMJ Financial notes payable plus interest with 151,655 common shares.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	(a) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All significant intercompany transactions and balances have been eliminated.
Cash and Cash Equivalents	(b) Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Government Grants and Investment Tax Credits Receivable	(c) Government Grants and Investment Tax Credits Receivable The Company’s accounts include claims for investment tax credits (“ITCs”) relating to scientific research activities of the Company prior to July 31, 2009. The qualification and recording of this activity for ITCs purposes is established by Canadian Income Tax authorities when the income tax returns for the period are assessed. ITCs were recognized in the statement of operations in the year in which the expenses were incurred. The Company no longer qualifies to receive substantial refunds of ITCs resulting from scientific research. Currently the majority of ITCs resulting from scientific research are carried forward to a time when the Company becomes tax paying at which time said ITCs are applicable against taxes payable.
Property and Equipment	(d) Property and Equipment Property and equipment is recorded at cost. Property and equipment is depreciated using methods and rates as follows: Furniture and Fixtures 20% declining balance Lab Equipment 20% declining balance Computer Equipment – Hardware 30% declining balance Computer Equipment – Software 50% declining balance Leasehold Improvements Straight-line over the lesser of the life of the asset or the life of the lease
Patents	(e) Patents Capitalized patent costs represent legal and application costs incurred to establish patents. Capitalized patent costs are amortized on a straight-line method over the related patent term. As patents are abandoned, the net book value of the patent is written off.
Impairment or Disposal of Long-Lived Assets	(f) Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of long-lived assets under the guidance of standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset.
Research and Development Costs	(g) Research and Development Costs Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of prototype products, including payroll costs. Amounts expected to be received from governments under Scientific Research Tax Credit arrangements are offset against current expenses. The Company recognizes revenue from restricted grants in the period in which the Company has incurred the expenditures in compliance with the specific restrictions.
Income Taxes	(h) Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in the authoritative guidance. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As there is no certainty that the Company will generate taxable income in the foreseeable future to utilize tax losses accumulated to date, no provision for ultimate tax reduction has been made in these financial statements. On November 1, 2007, the Company adopted the guidance issued for accounting for uncertainty in income taxes which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of the guidance and in subsequent periods. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as general and administrative expense. There are no uncertain tax positions as of October 31, 2015 and 2014.
Stock-Based Compensation	(i) Stock-Based Compensation The Company follows the authoritative guidance for stock-based compensation which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company has also considered the related guidance of the SEC. The Company estimates the fair value of stock options and shares issued as compensation to employees and directors as of the date of grant using the Black-Scholes pricing model and restricted stock based on the per share value. The Company also follows the guidance for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants which provides guidance on transactions in which (1) the fair value of the equity instruments is more reliably measurable than the fair value of the goods or services received and (2) the counterparty receives shares of stock, stock options, or other equity instruments in settlement of the entire transaction or, if the transaction is part cash and part equity instruments, in settlement of the portion of the transaction for which the equity instruments constitute the consideration. Options issued with a nominal exercise price in exchange for services rendered were measured at the fair value of the underlying services rendered on the date of grant. The expense is recorded to the statement of operations with a corresponding increase in share capital with no additional increase in the number of shares as they were legally not yet exercised.
Net Loss Per Common Share	(j) Net Loss Per Common Share Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on loss per share.
Comprehensive Income (Loss)	(k) Comprehensive Income (Loss) Other comprehensive income (loss) includes the foreign currency translation adjustments.
Concentration of Credit Risk	(l) Concentration of Credit Risk The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions.
Use of Estimates	(m) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. By their nature, these estimates are subject to uncertainty and the effect on the consolidated financial statements of changes in such estimates in future periods could be material.
Foreign Currency Translation	(n) Foreign Currency Translation The Company maintains its accounting records for its Canadian operations in Canadian dollars. Transactions in United States dollars (“USD”) are translated into Canadian dollars at rates in effect at the date of the transaction and gains or losses on such transactions are recorded at the time of settlement in the statement of operations. The Company’s reporting currency is the USD. Foreign denominated assets and liabilities of the Company are translated into USD at the prevailing exchange rates in effect at the end of the reporting period, the historical rate for stockholders’ deficiency and a weighted average of exchange rate in effect during the period for expenses, gains and losses. Adjustments that arise from translation into the reporting currency are recorded in the accumulated other comprehensive income (loss) component of stockholders’ deficiency.
Financial Instruments	(o) Financial Instruments The carrying values of cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature. Notes payable and convertible debentures approximate their fair value based upon recent issuances of the underlying debt.
Derivative Instruments	(p) Derivative Instruments The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
Beneficial Conversion Charge	(q) Beneficial Conversion Charge The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.
Recently Issued Accounting Standards	(r) Recently Issued Accounting Standards Revenue From Contracts With Customers In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods and services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 as amended is effective for the Company beginning in fiscal 2019. The Company is currently evaluating the impact of this pronouncement on its consolidated financial statements. Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Schedule of Property Plant and Equipment Depreciated Methods and Rates	Property and equipment is recorded at cost. Property and equipment is depreciated using methods and rates as follows: Furniture and Fixtures 20% declining balance Lab Equipment 20% declining balance Computer Equipment – Hardware 30% declining balance Computer Equipment – Software 50% declining balance Leasehold Improvements Straight-line over the lesser of the life of the asset or the life of the lease

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Cost and Accumulated Depreciation and Amortization of Property Plant and Equipment	The costs and accumulated depreciation and amortization of property and equipment are summarized as follows: October 31, 2015 2014 Furniture and Fixtures $ 12,120 $ 12,120 Lab Equipment 168,481 168,481 Computer Hardware 19,490 19,490 Computer Software 8,433 8,433 Leasehold Improvements 91,269 91,269 Total Property and Equipment 299,793 299,793 Less Accumulated Depreciation and Amortization 264,619 257,100 Property and Equipment, Net $ 35,174 $ 42,693

Patents (Tables)

Patents (Tables)	12 Months Ended
	Oct. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Costs and Accumulated Amortization of Patents	The costs and accumulated amortization of patents are summarized as follows: October 31, 2015 2014 Patents $ 146,079 $ 144,022 Less: Accumulated Amortization (43,139 ) (35,890 ) Patents, Net $ 102,940 $ 108,132 Weighted-Average Life 17 Years 17 Years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Deferred Tax Assets Consisted of the Effects of Temporary Differences	As of October 31, 2015 and 2014, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: October 31, 2015 2014 Temporary: Property and equipment $ 21,990 $ (24,092 ) Net operating loss carryforwards 17,568,933 18,640,188 Unrealized foreign exchange (71,958 ) 23,175 Investment tax credits 402,189 402,189 Transitional tax debits (25,076 ) (25,076 ) Unrealized loss (gain) on derivative liability 157,104 (37,181 ) Total Deferred Tax Assets 18,009,202 18,979,203 Valuation Allowance (18,009,202 ) (18,979,203 ) Net Deferred Income Taxes $ ▬ $ ▬
Canadian Combined Statutory Rate to the Company's Effective Tax Rate	A reconciliation of the Canadian combined statutory rate to the Company’s effective tax rate for the years ended October 31, 2015 and 2014 is as follows: October 31, 2015 2014 Statutory rate 28 % 28 % Decrease in income tax rate resulting from: Permanent differences (6.0 )% (1.3 )% Change in valuation allowance (22.0 )% (26.7 )% Effective tax rate 0.0 % 0.0 %

Accounts Payable and Accrued 34

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Oct. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	October 31, 2015 2014 Accounts Payable $ 181,102 $ 289,054 Income Tax Reserve 487,460 321,460 Research and Development 188,458 17,004 Investor Relations 10,104 11,738 Patent Application Costs 2.419 5,026 Legal Fees 301,154 316,127 Stock Exchange Listing 15,384 ▬ Accounting Fees 58,355 60,400 Total $ 1,244,446 $ 1,020,809

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Oct. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Weighted Average Exercise Options Price Outstanding – October 31, 2013 30,000 $ 0.90 Granted ▬ ▬ Forfeited/expired ▬ ▬ Exercised ▬ ▬ Outstanding – October 31, 2014 30,000 $ 0.90 Granted ▬ ▬ Forfeited/expired ▬ ▬ Exercised ▬ ▬ Outstanding – October 31, 2015 30,000 $ 0.90
Summarizes Information on Stock Options Outstanding	The following table summarizes information on stock options outstanding at October 31, 2015 Options Outstanding and Exercisable Weighted Number Weighted Average Outstanding Average Remaining Aggregate at Exercise Life Intrinsic October 31, 2015 Price (Years) Value 30,000 $ 0.90 3.75 30,000 3.75 $ 0

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
Summary of Notes Payable	A summary of the Notes at October 31, 2015 and 2014 is as follows: October 31, 2015 October 31, 2014 Convertible Note Payable, due February 20, 2015 $ - $ 12,529 Convertible Notes Payable, due May 23, 2015 - 105,000 Convertible Note Payable, due June 23, 2016 54,925 40,000 Convertible Note Payable, due October 22, 2015 - 35,000 Convertible Note Payable, due November 26, 2015 55,250 - Convertible Note Payable, due December 15, 2015 16,500 - Convertible Note Payable, due August 14, 2016 27,500 - Convertible Note Payable, due October 13, 2016 27,500 - Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $72,614 and $71,863 (109,061 ) (120,666 ) Total 72,614 71,863 Less: Current portion 72,614 71,863 Total Long-term portion $ - $ -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Oct. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Liabilities Measured on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis as of October 31, 2015 and 2014, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value: Quoted Prices in Significant Other Significant Total Increase (Reduction) Active Markets for Observable Unobservable in Fair Value Balance Sheet Identical Assets or Inputs Inputs October 31, 2014 Recorded at Location Liabilities (Level 1) (Level 2) (Level 3) Total October 31, 2014 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 201,260 $ 201,260 $ (142,054) Quoted Prices in Significant Other Significant Total Increase (Reduction) Active Markets for Observable Unobservable in Fair Value Balance Sheet Identical Assets or Inputs Inputs October 31, 2015 Recorded at Location Liabilities (Level 1) (Level 2) (Level 3) Total October 31, 2015 Liabilities: Derivative liability – on Notes Payable $ - $ - $ 344,086 $ 344,086 $ 611,427
Schedule of Fair Value of Estimated Derivative Liabilities Weighted Average Assumption	The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the derivative liability at October 31, 2015 and 2014: 2015 2014 Fair value $0.017-0.018 $0.058-0.060 Expected volatility 241-272 % 162%-169 % Dividend yield - - Expected term (in years) .06 - .95 .31-.94 Risk-free interest rate 0.11 % 0.11 %
Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the year ended October 31, 2015. 2015 2014 Balance at beginning of year $ 201,260 $ 99,702 Additions to derivative instruments 375,257 369,738 Change in fair value of derivative liabilities 611,427 (142,054 ) Settlements (843,858 ) (126,126 ) Balance at end of year $ 344,086 $ 201,260

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Oct. 31, 2015
Equity [Abstract]
Schedule of Warrants Outstanding	Outstanding warrants are as follows: October 31, 2015 2014 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016 250,000 250,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016 500,000 500,000 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016 500,000 500,000 Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including February 27, 2016 600,000 600,000 Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.14 per common share up to and including June 3, 2016 750,000 750,000 Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016 232,500 232,500 Issued to consultants August 5, 2013, entitling the holders to purchase 2,500,000 common shares in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023 2,500,000 2,500,000 Issued to consultants August 5, 2013, entitling the holders to purchase 1,500,000 common shares in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023 1,500,000 1,500,000 Issued to consultant September 3, 2013, entitling the holder to purchase 500,000 common shares in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018 500,000 500,000 Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016 250,000 250,000 Issued to shareholder November 7, 2013, entitling the holder to purchase 1 common shares in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 125,000 125,000 Total Warrants outstanding 8,457,500 8,457,500

Issuance of Common Stock (Table

Issuance of Common Stock (Tables)	12 Months Ended
	Oct. 31, 2015
Equity [Abstract]
Schedule of Common Stock Issue	During the year ended October 31, 2015 and 2014, the Company issued the following common shares: Year Ended October 31, 2015 Year Ended October 31, 2014 # of shares Amount # of shares Amount Issuance to third parties for services rendered 100,000 $ 3,045 679,615 $ 100,734 Issuance to third parties for cash 1,600,000 $ 40,000 200,000 $ 50,000 Issuance to third parties on exercise of conversion of notes payable 42,903,378 $ 422,874 1,352,991 $ 101,991 Issued to shareholder on conversion of shareholder’s loan 227,273 $ 22,856 - $ - Issued to debenture holders on exercise of conversion of debentures payable - $ - 9,427,576 $ 1,035,333 Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company. - $ - 296,538 $ -

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Oct. 31, 2015
Earnings Per Share [Abstract]
Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted (loss) per share: Years Ended October 31, 2015 2014 Weighted-average shares - basic 94,424,039 61,701,832 Effect of dilutive securities ▬ ▬ Weighted-average shares - diluted 94,424,039 61,701,832

Commitments and Contingent Li41

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Oct. 31, 2015
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Aggregate Minimum Annual Lease Commitments Under Non-Cancelable Operating Lease	Aggregate minimum annual lease commitments of the Company under the non-cancelable operating lease as of October 31, 2015 are as follows. (The Company is required in addition to pay a proportionate share of building operational expenses.) : Year Amount 2016 $ 42,473 2017 35,394 Total Minimum Lease Payments $ 77,867

Supplemental Disclosure of Ca42

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Oct. 31, 2015
Supplemental Cash Flow Information [Abstract]
Cash Flow Supplemental Disclosures	For the Year Ended October 31, 2015 2014 Cash paid during the period for: Interest $ 22,551 $ 16,901 Income Taxes ▬ ▬ Non-cash financing activities: Conversion of notes payable including principal, interest and original issue discount 422,874 101,991 Services rendered settled with common shares 3,045 100,734 Value of beneficial conversion feature and warrants issued with debentures issued during the year ▬ 745,121 Settlement of accrued legal by issuance of common shares ▬ 189,000 Settlement of shareholder loan with common shares 22,856 ▬

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 49,554,070	$ 47,637,746

Summary of Significant Accoun44

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Percentage of owned subsidiaries	100.00%

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Depreciated Methods and Rates (Details)	12 Months Ended
	Oct. 31, 2015
Furniture And Fixtures [Member]
Property plant and equipment percentage	20.00%
Property, plant and equipment, depreciation method	declining balance
Lab Equipment [Member]
Property plant and equipment percentage	20.00%
Property, plant and equipment, depreciation method	declining balance
Computer Equipment - Hardware [Member]
Property plant and equipment percentage	30.00%
Property, plant and equipment, depreciation method	declining balance
Computer Equipment - Software [Member]
Property plant and equipment percentage	50.00%
Property, plant and equipment, depreciation method	declining balance
Leasehold Improvements [Member]
Property, plant and equipment, depreciation method	Straight-line over the lesser of

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 7,519	$ 10,803

Property and Equipment - Schedu

Property and Equipment - Schedule of Cost and Accumulated Depreciation and Amortization of Property Plant and Equipment (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Furniture and Fixtures	$ 12,120	$ 12,120
Lab Equipment	168,481	168,481
Computer Hardware	19,490	19,490
Computer Software	8,433	8,433
Leasehold Improvements	91,269	91,269
Total Property and Equipment	299,793	299,793
Less Accumulated Depreciation and Amortization	264,619	257,100
Property and Equipment, Net	$ 35,174	$ 42,693

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Amortization expense	$ 7,248	$ 10,300
October 31, 2016 Through 2020 [Member]
Amortization expense	$ 7,250

Patents - Schedule of Costs and

Patents - Schedule of Costs and Accumulated Amortization of Patents (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
CostAndAccumulatedAmortizationLineItems [Line Items]
Patents, Net	$ 102,940	$ 108,132
Patents [Member]
CostAndAccumulatedAmortizationLineItems [Line Items]
Patents	146,079	144,022
Less: Accumulated Amortization	(43,139)	(35,890)
Patents, Net	$ 102,940	$ 108,132
Weighted-Average Life	17 years	17 years

Due to Shareholders (Details Na

Due to Shareholders (Details Narrative)	Oct. 31, 2015
Due To Shareholders Details Narrative
Percentage of demand and carries interest per annum	10.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2012
Operating Loss Carryforwards [Line Items]
Estimated penalties and interest	$ 408,000
General ownership change, description	In general, an ownership change may occur from certain transactions that increase the ownership of 5% stockholders in the stock of a corporation by more than 50 percentage points over a three year period.
Effective tax rate benefit recorded during period	0.00%	0.00%
Canadian Sources [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 7,457,000
Operating loss carry forwards expire term	expire from 2016 through 2035
Research and development tax credit received refund amount			$ 81,460
US Sources [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 45,532,000
Operating loss carry forwards expire term	expire from 2020 through 2034

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets Consisted of the Effects of Temporary Differences (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
Property and equipment	$ 21,990	$ (24,092)
Net operating loss carryforwards	17,568,933	18,640,188
Unrealized foreign exchange	(71,958)	23,175
Investment tax credits	402,189	402,189
Transitional tax debits	(25,076)	(25,076)
Unrealized loss (gain) on derivative liability	157,104	(37,181)
Total Deferred Tax Assets	18,009,202	18,979,203
Valuation Allowance	$ (18,009,202)	$ (18,979,203)
Net Deferred Income Taxes

Income Taxes - Canadian Combine

Income Taxes - Canadian Combined Statutory Rate to the Company's Effective Tax Rate (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
Statutory rate	28.00%	28.00%
Permanent differences	(6.00%)	(1.30%)
Change in valuation allowance	(22.00%)	(26.70%)
Effective tax rate	0.00%	0.00%

Accounts Payable and Accrued 54

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable	$ 181,102	$ 289,054
Income Tax Reserve	487,460	321,460
Research and Development	188,458	17,004
Investor Relations	10,104	11,738
Patent Application Costs	2,419	5,026
Legal Fees	301,154	$ 316,127
Stock Exchange Listing	15,384
Accounting Fees	58,355	$ 60,400
Total	$ 1,244,446	$ 1,020,809

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Equity [Abstract]
Stock based employee compensation related to stock options	$ 0	$ 0
Market price value per share	$ 0.04

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Common Stock Options Granted, Forfeited or Expired and Exercised Under Plan (Details) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Equity [Abstract]
Options, Outstanding beginning balance	30,000	30,000
Options, Granted
Options, Forfeited/Expired
Options, Exercised
Options, Outstanding ending balance	30,000	30,000
Weighted Average Exercise price, Beginning balance	$ 0.90	$ 0.90
Weighted Average Exercise price, Granted
Weighted Average Exercise price, Forfeited/Expired
Weighted Average Exercise price, Exercised
Weighted Average Exercise price, Ending balance	$ 0.90	$ 0.90

Stock-Based Compensation - Su57

Stock-Based Compensation - Summarizes Information on Stock Options Outstanding (Details)	12 Months Ended
	Oct. 31, 2015USD ($)$ / sharesshares
Options Outstanding and Exercisable, Number Outstanding	30,000
Options Outstanding and Exercisable, Weighted Average Remaining Life (Years)	3 years 9 months
Options Outstanding and Exercisable, Aggregate Intrinsic Value | $	$ 0
Weighted Average Excercise Price $0.90 [Member]
Options Outstanding and Exercisable, Number Outstanding	30,000
Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.90
Weighted Average Excercise Price $0.90 [Member]
Options Outstanding and Exercisable, Weighted Average Remaining Life (Years)	3 years 9 months

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)

Oct. 13, 2015

Aug. 14, 2015

Jul. 31, 2015

Jun. 22, 2015

Mar. 25, 2015

Dec. 15, 2014

Nov. 20, 2014

Nov. 12, 2014

May. 23, 2014

Nov. 19, 2012

Oct. 31, 2015

Oct. 31, 2013

NotesPayableLineItems [Line Items]

Line of credit facility, maximum borrowing capacity

$ 350,000

Increments in line of credit facility

50,000

Line of credit facility original issue discount

$ 50,000

Line of credit facility, interest rate percentage

5.00%

Lenders right relating to notes payable description

The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.

Conversion price per share

$ 0.23

Debt instrument lowest trading price percentage before conversion

60.00%

Line of credit facility common stock outstanding percentage

4.99%

Remaining indebtedness

$ 77,235

Pay the lender, description

the Company agreed that on the 15th of each month commencing July 2015 and ending June 2016, the Company would either pay the lender $6,436 or issue to the lender common shares in the equivalent dollar amount at a price equal to the average closing price of the common stock in the five trading days prior to the scheduled payment date. During the year the company paid one installment in cash and a total of 655,150 common shares for three installments.

Payments to lender

$ 6,436

Debt in exchange to purchase common stock shares

$ 210,355

Notes in the principal amount

$ 422,874

Notes exchanged for common stock shares issued

42,903,378

LG Capital Funding, LLC and Adar Bays, LLC [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 52,500

Percentage of promissory notes

8.00%

Debt instrument maturity Date

May 23, 2015

LG Capital Funding [Member]

NotesPayableLineItems [Line Items]

Percentage of debt converted into stock discount

42.00%

Debt penalties below 60 days of issuance

130.00%

Debt penalties After 60 days of issuance

140.00%

Convertible note payable

$ 36,000

Chicago Ventures [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 50,000

Percentage of promissory notes

10.00%

Percentage of debt converted into stock discount

40.00%

Debt closing price term

15 days

IBC Funds, LLC [Member]

NotesPayableLineItems [Line Items]

Percentage of debt converted into stock discount

40.00%

Debt closing price term

15 days

Debt in exchange to purchase common stock shares

$ 78,026

LG Capital Funding, LLC [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 52,500

Percentage of promissory notes

8.00%

Percentage of debt converted into stock discount

42.00%

Debt closing price term

15 days

Debt in exchange to purchase common stock shares

$ 36,000

Debt instrument maturity year

1 year

Adar Bays [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 52,500

Percentage of promissory notes

8.00%

Debt instrument maturity Date

Nov. 26, 2015

Percentage of debt converted into stock discount

40.00%

Debt closing price term

10 days

Auctus Private Equity Fund, LLC [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 55,250

Percentage of promissory notes

8.00%

Percentage of debt converted into stock discount

45.00%

Debt closing price term

15 days

Debt instrument maturity year

9 months

Iliad Research and Trading LLC [Member]

NotesPayableLineItems [Line Items]

Proceeds from issuance of promissory note

$ 27,500

$ 27,500

Percentage of promissory notes

10.00%

10.00%

Percentage of debt converted into stock discount

40.00%

40.00%

Debt closing price term

15 days

15 days

Debt instrument maturity year

1 year

1 year

Three Installments [Member]

NotesPayableLineItems [Line Items]

Common shares paid installment

655,150

Notes Payable - Summary of Note

Notes Payable - Summary of Notes Payable (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Short-term Debt [Line Items]
Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $133,843 and $71,863	$ (109,061)	$ (120,666)
Total	72,614	71,863
Less: Current portion	72,614	$ 71,863
Total Long-term portion	$ 0
Convertible Note Payable, Due February 20, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		$ 12,529
Convertible Notes Payable, Due May 23, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		105,000
Convertible Note Payable, Due June 23, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$ 54,925	40,000
Convertible Note Payable, Due October 22, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		$ 35,000
Convertible Note Payable, due November 26, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$ 55,250
Convertible Note Payable, due December 15, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	16,500
Convertible Note Payable, due August 14, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	27,500
Convertible Note Payable, due October 13, 2016 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$ 27,500

Notes Payable - Summary of No60

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Net of accumulated amortization	$ 72,614	$ 71,863
Convertible Note Payable, Due February 20, 2015 [Member]
Convertible Note Payable, maturity date	Feb. 20, 2015	Feb. 20, 2015
Convertible Notes Payable, Due May 23, 2015 [Member]
Convertible Note Payable, maturity date	May 23, 2015	May 23, 2015
Convertible Note Payable, Due June 23, 2016 [Member]
Convertible Note Payable, maturity date	Jun. 23, 2016	Jun. 23, 2016
Convertible Note Payable, Due October 22, 2015 [Member]
Convertible Note Payable, maturity date	Oct. 22, 2015	Oct. 22, 2015
Convertible Note Payable, due November 26, 2015 [Member]
Convertible Note Payable, maturity date	Nov. 26, 2015	Nov. 26, 2015
Convertible Note Payable, due December 15, 2015 [Member]
Convertible Note Payable, maturity date	Dec. 15, 2015	Dec. 15, 2015
Convertible Note Payable, due August 14, 2016 [Member]
Convertible Note Payable, maturity date	Aug. 14, 2016	Aug. 14, 2016
Convertible Note Payable, due October 13, 2016 [Member]
Convertible Note Payable, maturity date	Oct. 13, 2016	Oct. 13, 2016

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Nov. 19, 2012
Derivative liabilities	$ 344,086	$ 201,260
Conversion price per share			$ 0.23
Fair value assumptions, risk free interest rate	0.11%	0.11%
Fair value assumptions, expected term	1 year
Fair value assumptions, expected dividend rate	0.00%
Minimum [Member]
Conversion price per share	$ 0.017
Fair value assumptions, expected term	22 days	3 months 22 days
Fair value assumptions, expected volatility rate	241.00%
Maximum [Member]
Conversion price per share	$ 0.018
Fair value assumptions, expected term	11 months 12 days	11 months 9 days
Fair value assumptions, expected volatility rate	272.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Liabilities Measured on Recurring Basis (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Derivative liability on notes payable	$ 344,086	$ 201,260
Total Increase (Reduction) in Fair Value Recorded	$ 611,427	$ (142,054)
Quoted Prices In Active Markets For Identical Assets Or Liabilities (Level 1) [Member]
Derivative liability on notes payable
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability on notes payable
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability on notes payable	$ 344,086	$ 201,260

Fair Value Measurements - Sch63

Fair Value Measurements - Schedule of Fair Value of Estimated Derivative Liabilities Weighted Average Assumption (Details) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Dividend yield
Expected term (in years)	1 year
Risk-free interest rate	0.11%	0.11%
Minimum [Member]
Fair value	$ 0.017	$ 0.058
Expected volatility	241.00%	162.00%
Expected term (in years)	22 days	3 months 22 days
Maximum [Member]
Fair value	$ 0.018	$ 0.060
Expected volatility	272.00%	169.00%
Expected term (in years)	11 months 12 days	11 months 9 days

Fair Value Measurements - Sch64

Fair Value Measurements - Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Fair Value Disclosures [Abstract]
Balance at beginning of year	$ 201,260	$ 99,702
Additions to derivative instruments	375,257	369,738
Change in fair value of derivative liabilities	611,427	(142,054)
Settlements	(843,858)	(126,126)
Balance at end of year	$ 344,086	$ 201,260

Debentures Payable (Details Nar

Debentures Payable (Details Narrative) - USD ($)	Sep. 17, 2014	Jun. 30, 2013	May. 31, 2013	Feb. 28, 2013	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013	Nov. 19, 2012
Short-term Debt [Line Items]
Conversion price per share								$ 0.23
Debt instrument face amount					$ 422,874
Proceeds from warrants							$ 306,900
Risk-free interest rate					0.11%	0.11%
Expected life term					1 year
Expected dividend rate					0.00%
Number of shares issued for conversion					42,903,378
Minimum [Member]
Short-term Debt [Line Items]
Conversion price per share					$ 0.017
Expected life term					22 days	3 months 22 days
Expected volatility rate					241.00%
Maximum [Member]
Short-term Debt [Line Items]
Conversion price per share					$ 0.018
Expected life term					11 months 12 days	11 months 9 days
Expected volatility rate					272.00%
Warrant [Member]
Short-term Debt [Line Items]
Debt instrument term		3 years	3 years	3 years
Series A Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt conversation amount				$ 288,584
Debt instrument, interest rate terms				10.00%
Debt instrument term				3 years
Conversion price per share	$ 0.11			$ 0.25
Debt instrument, redemption description				The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.25 per share at any time up to three years.
Number of shares issued for conversion	9,427,576
Series B Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate terms		10.00%	10.00%
Debt instrument term		3 years	3 years
Conversion price per share	$ 0.11	$ 0.25	$ 0.25
Debt instrument, redemption description		The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.	The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.
Debt instrument face amount		$ 148,653	$ 500,000
Proceeds from warrants						$ 343,996
Increase in additional paid in capital and debt discount						$ 650,896
Number of shares issued for conversion	9,427,576
Series B Convertible Debenture [Member] | Warrant [Member]
Short-term Debt [Line Items]
Risk-free interest rate						0.18%
Expected life term						3 years
Expected dividend rate						0.00%
Series B Convertible Debenture [Member] | Warrant [Member] | Minimum [Member]
Short-term Debt [Line Items]
Expected volatility rate						176.00%
Series B Convertible Debenture [Member] | Warrant [Member] | Maximum [Member]
Short-term Debt [Line Items]
Expected volatility rate						195.00%
Debt Conversion Price One [Member] | Warrant [Member]
Short-term Debt [Line Items]
Conversion price per share						$ 0.25
Debt Conversion Price Two [Member] | Warrant [Member]
Short-term Debt [Line Items]
Conversion price per share						$ 0.15
Convertible Debenture [Member]
Short-term Debt [Line Items]
Additional beneficial conversion charge						$ 745,121
Convertible Debenture [Member] | Minimum [Member]
Short-term Debt [Line Items]
Conversion price per share						$ 0.11
Convertible Debenture [Member] | Maximum [Member]
Short-term Debt [Line Items]
Conversion price per share						$ 0.25

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - shares	Oct. 31, 2015	Oct. 31, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding	8,457,500	8,332,500
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	600,000	600,000
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.14 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	750,000	750,000
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	232,500	232,500
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 2,500,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,500,000	2,500,000
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 1,500,000 Common Shares In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,500,000	1,500,000
Issued To Consultant September 3, 2013, Entitling The Holder To Purchase 500,000 Common Shares In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Shareholder October 29, 2013, Entitling The Holder To Purchase 250,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Shareholder November 7, 2013, Entitling The Holder To Purchase 1 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	125,000	125,000

Warrants - Schedule of Warran67

Warrants - Schedule of Warrants Outstanding (Details) (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.30	$ 0.30
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.50	$ 0.50
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.75	$ 0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 1	$ 1
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.75	$ 0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Feb. 27, 2016	Feb. 27, 2016
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.14 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.14	$ 0.14
Warrant, last exercisable date	Jun. 3, 2016	Jun. 3, 2016
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Jun. 3, 2016	Jun. 3, 2016
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 2,500,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	2,500,000	2,500,000
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Aug. 4, 2023	Aug. 4, 2023
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 1,500,000 Common Shares In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1,500,000	1,500,000
Warrants, exercise price	$ 0.10	$ 0.10
Warrant, last exercisable date	Aug. 4, 2023	Aug. 4, 2023
Issued To Consultant September 3, 2013, Entitling The Holder To Purchase 500,000 Common Shares In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	500,000	500,000
Warrants, exercise price	$ 0.50	$ 0.50
Warrant, last exercisable date	Jul. 31, 2018	Jul. 31, 2018
Issued To Shareholder October 29, 2013, Entitling The Holder To Purchase 250,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	250,000	250,000
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Oct. 29, 2016	Oct. 29, 2016
Issued To Shareholder November 7, 2013, Entitling The Holder To Purchase 1 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$ 0.15	$ 0.15
Warrant, last exercisable date	Nov. 7, 2016	Nov. 7, 2016

Authorized Share Capital (Detai

Authorized Share Capital (Details Narrative) - $ / shares	Apr. 23, 2010	Oct. 31, 2015	Oct. 31, 2014	Jan. 17, 2013	Sep. 30, 2009
Common stock shares, authorized		150,000,000	150,000,000		500,000,000
Excess of common stock authorized					650,000,000
Common stock, par value		$ 0.00001	$ 0.00001		$ 0.00001
Capital stock issued, par value					$ 0.00001
Common stock authorized shares increased				150,000,000
Minimum [Member]
Capital stock authorized					70,044,000
Maximum [Member]
Capital stock authorized					700,440,000
Board of Directors Chairman [Member]
Common stock shares, authorized	65,000,000
Reverse stock split	ratio of one-for-ten and the reverse split was effective June 20, 2010.
Preferred Stock [Member]
Capital stock authorized					5,000,000
Common Stock [Member]
Capital stock authorized					65,000,000
Series 2 Class B Common Stock [Member]
Capital stock authorized					40,000
Series 3 Class B Common Stock [Member]
Capital stock authorized					4,000

Issuance of Common Stock (Detai

Issuance of Common Stock (Details Narrative)	Oct. 31, 2015shares
Equity [Abstract]
Reserved in treasury common shares for possible conversion of exercise options, warrants and debt	24,700,000

Issuance of Common Stock - Sche

Issuance of Common Stock - Schedule of Common Stock Issue (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Issuance to third parties for services rendered	$ 3,045
Issuance to third parties for services rendered, shares	100,000
Issuance to third parties for cash	$ 40,000
Issuance to third parties for cash, shares	1,600,000
Issuance to third parties on exercise of conversion of notes payable	$ 422,874
Issuance to third parties on exercise of conversion of notes payable, shares	42,903,378
Issued to shareholder on conversion of shareholder's loan	$ 22,856
Issued to shareholder on conversion of shareholder's loan, shares	227,273
Issued to debenture holders on exercise of conversion of debentures payable
Issued to debenture holders on exercise of conversion of debentures payable, shares
Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company.
Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company, shares
Common Stock [Member]
Issuance to third parties for services rendered		$ 100,734
Issuance to third parties for services rendered, shares		679,615
Issuance to third parties for cash	$ 16	$ 50,000
Issuance to third parties for cash, shares	1,600,000	200,000
Issuance to third parties on exercise of conversion of notes payable		$ 101,991
Issuance to third parties on exercise of conversion of notes payable, shares		1,352,991
Issued to shareholder on conversion of shareholder's loan
Issued to shareholder on conversion of shareholder's loan, shares
Issued to debenture holders on exercise of conversion of debentures payable		$ 1,035,333
Issued to debenture holders on exercise of conversion of debentures payable, shares		9,427,576
Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company.
Issued to minority shareholders on exchange of their shares in subsidiary for shares in the Company, shares		296,538

Redemption of Class B Common 71

Redemption of Class B Common Stock (Details Narrative)	Feb. 28, 2011$ / shares
Class B Common Stock [Member]
Redemption price, par value	$ 0.00001

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Earnings Per Share [Abstract]
Incremental shares excluded from computation of diluted earnings per share	18,621,774	12,195,822

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Earnings Per Share [Abstract]
Weighted-average shares - basic	94,424,039	61,701,832
Effect of dilutive securities
Weighted-average shares - diluted	94,424,039	61,701,832

Commitments and Contingent Li74

Commitments and Contingent Liabilities (Details Narrative) - USD ($)	Jan. 03, 2014	Apr. 22, 2009	Oct. 31, 2015	Oct. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Lease expense			$ 61,137	$ 70,374
Former employee related claims		$ 514,000
Litigation amount	$ 10,000
Payment of litigation amount by shares	700,000

Commitments and Contingent Li75

Commitments and Contingent Liabilities - Schedule of Aggregate Minimum Annual Lease Commitments (Details)	Oct. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 42,473
2,017	35,394
Total Minimum Lease Payments	$ 77,867

Supplemental Disclosure of Ca76

Supplemental Disclosure of Cash Flow Information - Cash Flow Supplemental Disclosures (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for: Interest	$ 22,551	$ 16,901
Cash paid during the period for: Income taxes
Non-cash financing activities: Conversion of notes payable including principal, interest and original issue discount	$ 422,874	$ 101,991
Non-cash financing activities: Services rendered settled with common shares	$ 3,045	100,734
Non-cash financing activities: Value of beneficial conversion feature and warrants issued with debentures issued during the year		745,121
Non-cash financing activities: Settlement of accrued legal by issuance of common shares		$ 189,000
Non-cash financing activities: Settlement of shareholder loan with common shares	$ 22,856

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Jan. 15, 2016USD ($)shares

Dec. 21, 2015USD ($)shares

Dec. 15, 2015USD ($)shares

Nov. 25, 2015USD ($)

Nov. 13, 2015USD ($)shares

Nov. 04, 2015USD ($)

Nov. 03, 2015CADshares

Oct. 31, 2015USD ($)$ / sharesshares

Oct. 31, 2013shares

Nov. 15, 2015USD ($)

Nov. 03, 2015USD ($)$ / shares

Nov. 03, 2015CAD

Oct. 31, 2014USD ($)$ / shares

Sep. 30, 2009$ / shares

Original debt amount

$ 422,874

Conversion of notes payable into common stock | shares

42,903,378

Common stock, par value | $ / shares

$ 0.00001

$ 0.00001

$ 0.00001

Notes payable

$ (72,614)

$ (71,863)

Subsequent Event [Member]

Original debt amount

$ 7,279

Conversion of notes payable into common stock | shares

205,000

Subsequent Event [Member] | 173 Corp [Member]

Advanced by related party

$ 288,126

Subsequent Event [Member] | Individuals [Member]

Note payable bearing interest rate

10.00%

Loan received

$ 227,894

Subsequent Event [Member] | JMJ [Member]

Original debt amount

$ 6,436

$ 6,436

Conversion of notes payable into common stock | shares

151,655

135,614

160,425

Notes payable

$ 6,436

Subsequent Event [Member] | Bay Private Equity Inc [Member]

Note payable bearing interest rate

8.00%

Notes payable

$ 50,000

Common stock of discount rate

55.00%

Subsequent Event [Member] | Firstfire Global Opportunities Fund LLP [Member]

Original debt amount

$ 160,500

Note payable bearing interest rate

4.00%

Debt instrument conversion description

Should the company fail to pay said Principal Sum plus interest on or before May 25, 2016, Firstfire may convert the Promissory Note into $240,750 worth of common shares at the lower of $.15 per common share or 40% of the lowest selling price of the common shares in the ten (10) days preceding the conversion date.

Subsequent Event [Member] | CDN [Member]

Note payable maturity year

5 years

Change in convertible debt | CAD

CAD 1,000,000

Subsequent Event [Member] | Sellers [Member]

Note payable bearing interest rate

8.00%

8.00%

Conversion of notes payable into common stock | shares

20,000,000

Common stock, par value | $ / shares

$ 0.00001

Warrant issued to purchase common stock | shares

10,000,000

Note payable maturity year

3 years

Stock exercise price per share | $ / shares

$ 0.50

Subsequent Event [Member] | Sellers [Member] | CDN [Member]

Original debt amount | CAD

CAD 10,000,000

Secured debt | CAD

2,900,000

Notes payable

$ 50,000

Advanced by related party | CAD

CAD 50,000